

Capecitabine Market to Grow at 8.7% CAGR from 2025-2029

*The Business Research Company's
Capecitabine Global Market Report 2025
– Market Size, Trends, And Forecast 2025-
2034*

LONDON, GREATER LONDON, UNITED
KINGDOM, November 24, 2025
/EINPresswire.com/ -- What Is The
[Capecitabine Market](#) Size And
Growth?

The market size for capecitabine has seen significant growth in the past few years. It's projected to rise from \$2.22 billion in 2024 to \$2.41 billion in 2025, with a compound annual growth rate (CAGR) of 8.1%. The historical growth is mainly due to advancements in chemotherapy, the convenience of oral administration, regulatory approvals, availability of treatment, and recommendations by oncologists.



Get 20% Off All Global
Market Reports With Code
ONLINE20 – Stay Ahead Of
Trade Shifts,
Macroeconomic Trends, And
Industry Disruptors
”

*The Business Research
Company*

The market size of capecitabine is projected to witness robust expansion in the coming years, reaching "\$3.36 billion by 2029" with an 8.7% compound annual growth rate (CAGR). The significant growth anticipated in the forecast period is attributed to factors such as extended indications, investigations into combined therapies, developments in healthcare infrastructure, government-led initiatives, and its adoption in emerging nations.

Noteworthy trends anticipated during the forecast period encompass targeted therapy combinations, increased utilization in adjuvant scenarios, treatment guided by biomarkers, advanced pharmacogenomics, and telehealth monitoring.

Download a free sample of the capecitabine market report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=12240&type=smp>

What Are The Current Leading Growth Drivers For Capecitabine Market?

The surge in cancer cases is projected to boost the growth of the capecitabine market in the

The Business
Research Company

The Business Research Company



future. Cancer refers to a wide range of diseases that occur when cells in the body begin to multiply uncontrollably, surpass their normal boundaries, and either spread to other organs or infiltrate surrounding body parts. Capecitabine, a chemotherapy drug, is used in the treatment of cancer, where it's enzymatically transformed into fluorouracil, an antimetabolite in the tumor. This process inhibits DNA synthesis and decelerates the growth of tumor tissue. For example, in May 2024, the National Cancer Institute, a U.S. government agency, reported that cancer remains a leading cause of mortality globally, accounting for 20 million new cases and 9.7 million deaths in 2022. These numbers are predicted to increase to 29.9 million cases and 15.3 million deaths by 2040. Hence, the escalating prevalence of cancer is bolstering the growth of the capecitabine market.

Which Companies Are Currently Leading In The Capecitabine Market?

Major players in the Capecitabine include:

- Teva Pharmaceuticals Inc
- Mylan N.V
- Hikma Pharmaceuticals PLC
- Cipla Inc
- Dr. Reddy's Laboratories Ltd
- Fresenius SE & Co. KGaA
- Sun Pharmaceutical Industries Limited
- Genentech Inc.
- Accord Healthcare Ltd
- Hengrui Medicine

What Are The Main Trends, Positively Impacting The Growth Of Capecitabine Market?

A rising trend in the behavioral rehabilitation market is product innovation. Major players in the capecitabine market are pivoting towards the development of generic tablets to boost their market revenues. For example, Camber Pharmaceuticals, a pharmaceutical company based in the US, in August 2024, introduced Generic Xeloda (Capecitabine Tablets, USP) as of August 28, 2024. This orally taken chemotherapy drug is employed to tackle different cancers, including breast and colorectal, by suppressing the synthesis of DNA in cancer cells. The launch of Generic Xeloda® demonstrates Camber's dedication to offer high-quality and cost-effective substitutes for branded medications, improving access of patients to mandatory cancer treatments. This product launch aligns with the company's broader aspiration to enlarge its product range and satisfy the increasing market demand.

How Is The Capecitabine Market Segmented?

The capecitabine market covered in this report is segmented –

- 1) By Drug Type: Branded, Generic
- 2) By Drug Formulation: Tablet, Capsules
- 3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
- 4) By Application: Colon Cancer, Rectal Cancer, Breast Cancer, Gastric Cancer, Other Applications

5) By End-Users: Hospitals, Homecare, Specialty Centers, Other End-Users

Subsegments:

- 1) By Branded: Specific Brand Names, Market Share Of Leading Brands
- 2) By Generic: Different Manufacturers Producing Generics, Pricing Variations Among Generics, Regulatory Approvals

View the full capecitabine market report:

<https://www.thebusinessresearchcompany.com/report/capecitabine-global-market-report>

Which Is The Dominating Region For The Capecitabine Market?

In 2024, North America led in the Capecitabine market with expected growth projections. The report on the Capecitabine market includes coverage of regions such as Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East, and Africa.

Browse Through More Reports Similar to the Global Capecitabine Market 2025, By [The Business Research Company](#)

Engine Turbine And Power Transmission Equipment Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/engine-turbine-and-power-transmission-equipment-global-market-report>

Wind Turbine Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/wind-turbine-global-market-report>

Wind Turbine Casting Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/wind-turbine-casting-global-market-report>

Speak With Our Expert:

Saumya Sahay

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email: saumyas@tbrc.info

The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:

• LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

Oliver Guirdham

The Business Research Company

+44 7882 955267

info@tbrc.info

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/869137058>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.